Evidence map›Paper›PMID 40324960›Full record

ArticleJournal of neuromuscular diseases2025

Application of the ENCALS predictive survival model in assessing the effect of the 24/44 inclusion criteria in FORTITUDE-ALS.

Tyrell Simkins Lead, Jeremy M Shefner, Stuart Kupfer, Fady I Malik, Lisa Meng, Stacy A Rudnicki, Jenny Wei, Ruben Pa van Eijk

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuromuscular diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tyrell Simkins LeadCytokinetics Incorporated, South San Francisco, CA, USA.ORCID 0000-0002-6063-174X
Jeremy M ShefnerBarrow Neurological Institute, University of Arizona, Phoenix, AZ, USA.
Stuart KupferCytokinetics Incorporated, South San Francisco, CA, USA.
Fady I MalikCytokinetics Incorporated, South San Francisco, CA, USA.
Lisa MengCytokinetics Incorporated, South San Francisco, CA, USA.
Stacy A RudnickiCytokinetics Incorporated, South San Francisco, CA, USA.
Jenny WeiCytokinetics Incorporated, South San Francisco, CA, USA.
Ruben Pa van EijkDepartment of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

FORTITUDE-ALS was a study evaluating reldesemtiv in people living with ALS. Post-hoc analysis identified larger treatment effects in those with symptom onset ≤24 months and baseline ALSFRS-R ≤ 44 (24/44 criteria). Using the ENCALS risk score (RS), we analyzed how the 24/44 criteria changed the eligible population. Of the 272 participants meeting the 24/44 criteria, 73% had very short to intermediate RS compared to 18% not meeting the criteria. Though the 24/44 criteria enriched the FORTITUDE-ALS population with rapidly progressing patients, they did not completely exclude all patients with a very long predicted survival.

Indexed as

Amyotrophic Lateral SclerosisAgedDisease ProgressionFemaleHumansMaleMiddle AgedALSclinical trials designENCALS survival prediction modelFORTITUDE-ALS

Identifiers

PMID40324960
PMCPMC13142887

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.